Mary Dibiase Biography and Net Worth

COO of X4 Pharmaceuticals

Dr. DiBiase has served as X4’s Chief Operating Officer since September 2021, having joined the company in June 2017 and previously serving in a variety of senior management roles across Technical Operations, Quality, and Program Management. Prior to joining X4, she was Vice President, Technical Operations and Program Management at Epirus Biopharmaceuticals, a small biosimilar company working to expand access to biosimilar products across the globe. Other previous roles have included Vice President, Product Operations, Specialty Care Business Unit for Pfizer Global Supply, and multiple positions of increasing responsibility throughout her 16-year tenure at Biogen that included Senior Director, CMC Management, Program Executive for Avonex®, and Associate Director, Pharmaceutical Science and Technology. Dr. DiBiase received a B.Pharm. from the University of London, a Ph.D. from the University of Rhode Island, and she completed the Executive Leadership Program at Bentley University’s McCallum Graduate School of Business.

What is Mary Dibiase's net worth?: The estimated net worth of Mary Dibiase is at least $57,608.32 as of January 24th, 2025. Dr. Dibiase owns 16,366 shares of X4 Pharmaceuticals stock worth more than $57,608 as of May 30th. This net worth approximation does not reflect any other investments that Dr. Dibiase may own. Learn More about Mary Dibiase's net worth.
How do I contact Mary Dibiase?: The corporate mailing address for Dr. Dibiase and other X4 Pharmaceuticals executives is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. X4 Pharmaceuticals can also be reached via phone at (857) 529-8300 and via email at ir@arsanis.com. Learn More on Mary Dibiase's contact information.
Has Mary Dibiase been buying or selling shares of X4 Pharmaceuticals?: Mary Dibiase has not been actively trading shares of X4 Pharmaceuticals over the course of the past ninety days. Most recently, Mary Dibiase sold 741 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $13.50, for a transaction totalling $10,003.50. Following the completion of the sale, the chief operating officer now directly owns 16,366 shares of the company's stock, valued at $220,941. Learn More on Mary Dibiase's trading history.
Who are X4 Pharmaceuticals' active insiders?: X4 Pharmaceuticals' insider roster includes Mark Baldry (Chief Commercial Officer), Mary Dibiase (COO), Derek Meisner (General Counsel), Adam Mostafa (CFO), Paula Ragan (CEO), and Michael Wyzga (Director). Learn More on X4 Pharmaceuticals' active insiders.
Are insiders buying or selling shares of X4 Pharmaceuticals?: During the last twelve months, X4 Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,032 shares worth more than $2,559.36. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 26,111 shares worth more than $412,578.00. The most recent insider tranaction occured on May, 16th when insider Mark Baldry bought 1,032 shares worth more than $2,559.36. Insiders at X4 Pharmaceuticals own 2.4% of the company. Learn More about insider trades at X4 Pharmaceuticals.
Information on this page was last updated on 5/16/2025.

Mary Dibiase Insider Trading History at X4 Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/24/2025	Sell	741	$13.50	$10,003.50	16,366
10/7/2024	Sell	2,256	$17.10	$38,577.60	15,068
3/11/2024	Sell	513	$26.40	$13,543.20	9,725
2/12/2024	Sell	122	$30.30	$3,696.60	10,238
11/1/2023	Sell	2,256	$21.90	$49,406.40	10,361
9/8/2023	Sell	88	$37.50	$3,300.00	4,929
6/30/2023	Sell	15	$56.70	$850.50	5,017
6/23/2023	Sell	28	$57.90	$1,621.20	5,033
6/15/2023	Sell	28	$66.90	$1,873.20	5,061
2/13/2023	Sell	144	$27.90	$4,017.60	5,696

Mary Dibiase Buying and Selling Activity at X4 Pharmaceuticals

X4 Pharmaceuticals Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $3.34

$3.32

$3.52

50 Day Range

MA: $5.02

$2.71

$8.13

2 Week Range

Now: $3.34

$2.67

$33.90

Volume

46,442 shs

Average Volume

99,851 shs

Market Capitalization

$19.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73